about
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeSystematic adjudication of myocardial infarction end-points in an international clinical trialDisagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA GuidelineAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research instituteHeart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group ReportPractical management of anticoagulation in patients with atrial fibrillationInternational variation in the use of evidence-based medicines for acute coronary syndromesCurrent perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategiesEfficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarctionMedication performance measures and mortality following acute coronary syndromesTreating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events)Persistence of the prothrombotic state after acute coronary syndromes: implications for treatmentImpact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureThe failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac eventsPatient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capabilitySustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trialLow molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus studyAdherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational studyFrom guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)Lessons learned from a clinical trialReducing cardiac events after acute coronary syndromesTiming of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trialsRationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networksA comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery diseaseDabigatran versus warfarin in patients with mechanical heart valvesDevelopment of systems of care for ST-elevation myocardial infarction patients: the primary percutaneous coronary intervention (ST-elevation myocardial infarction-receiving) hospital perspectiveSequence variants affecting eosinophil numbers associate with asthma and myocardial infarctionRoger et al. respond to "future of population studies"Strategic transformation of population studies: recommendations of the working group on epidemiology and population sciences from the National Heart, Lung, and Blood Advisory Council and Board of External ExpertsGenome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysmDronedarone in High-Risk Permanent Atrial FibrillationGene expression patterns in peripheral blood correlate with the extent of coronary artery disease.Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studiesRegional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodologyPrehospital system delay in ST-segment elevation myocardial infarction care: a novel linkage of emergency medicine services and in hospital registry data.Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data).In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry.
P50
Q22242088-B8F1D33E-E2E5-459B-8042-39D96B460778Q24623137-4CE2EBFC-49E0-46F0-8932-A3962BC47782Q24805625-1F8DCFA4-5CC0-4D5A-BE75-E4ECE3A353F4Q24805692-BC855342-7C35-45ED-B73D-6ADB45D017F8Q26779649-2C43BE3A-0B9D-4A2B-9EF1-8906B64002ACQ26851235-502F3C77-5B77-4C40-9938-E6C7E93DE748Q28078934-36381465-0C5A-4B5D-8CB1-406302BE86D4Q28084915-AAC4AA61-4EE2-442D-9A6B-5D04B91C60E0Q28166289-7BCD4336-EA7D-4DC0-A369-CF84A5C3FCACQ28166395-11E14CA9-08BA-4AEC-B02E-2102CFC6E313Q28168974-45506FC0-F1C6-471C-8AB6-91FDF94BE1DBQ28186198-145AFE80-5063-43A8-AA6E-8E8B6F2272D7Q28192219-DA8DCE01-3645-48E7-901F-46CA0EBE64F9Q28192334-1C18A642-ADDA-403F-B1CA-EE91E0E8F68AQ28192602-33C2249C-5EA2-401F-96FE-DB0904D1F3B2Q28193081-81D1C7E3-7EE0-4445-97B8-80A9A21AA2FCQ28193850-33862ABE-2288-4567-9DF3-F851632CA7BCQ28195519-53E5A71A-DA47-4D4E-BF5D-838066B19AEDQ28195763-A631F06B-02C6-48BA-807F-8F252AB283DAQ28198544-10903E01-A1F8-455B-BB86-EC8840188F0AQ28198910-0F8A5303-9200-468C-BA2F-A5A0B3AD53C7Q28211220-BB3ED043-4E85-4098-94D6-E68564261B15Q28212313-7A022A8F-101A-458F-9EB9-0201E2314C43Q28221803-6FAA7300-BE19-4BDD-9B30-CA767843DE23Q28265129-C29464F3-AA83-4DDB-84E5-27A507994D55Q28267020-98AD8188-DF1C-47B5-A7CF-96CE77A81B46Q28297637-1B20078C-550D-4785-9D42-08711BBE9E39Q28304424-2CA79DBB-07D3-457A-9E66-81281322FE66Q28308221-891EECA0-B232-4C7B-9C9F-EC95AACA66C8Q28649683-EC727D02-B597-4448-958E-BA1A2E7A6200Q28651477-D491E4EF-0E10-4164-A81F-147B7B6E9139Q28943557-2439A4FC-546B-4840-9F5C-CEDC749CF2DAQ29397457-7E2C90F8-4FDC-4059-9EA6-6F1CFAF2FA3BQ30486777-6D73DC37-4BF5-4379-AD66-7A50AB6D0F98Q30499949-A6B6A487-574B-431D-9A8B-D4D127A6C8DBQ30572904-85904A2A-3BFD-4748-8676-2A5C86055D50Q30596385-471F541C-0D8A-4CC3-8AA2-5D752B5A8079Q30705164-1CC78E67-2AAB-4B9D-A7BE-99587CEA1533Q30840892-70E4C511-1C52-4380-94A9-5DF5C6FFD249Q30875802-9EB063EE-41DD-4AC9-AEA9-3C2A7D173E0F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher B. Granger
@ast
Christopher B. Granger
@en
Christopher B. Granger
@es
Christopher B. Granger
@nl
type
label
Christopher B. Granger
@ast
Christopher B. Granger
@en
Christopher B. Granger
@es
Christopher B. Granger
@nl
prefLabel
Christopher B. Granger
@ast
Christopher B. Granger
@en
Christopher B. Granger
@es
Christopher B. Granger
@nl
P106
P21
P31
P496
0000-0002-0045-3291